CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0000938: OsteopeniaHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1056 High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT) Wiki 1.00
drug2692 Wellness Wiki 1.00
drug602 Colchicine 1 MG Oral Tablet Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001851 Bone Diseases, Metabolic NIH 1.00

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Effects of an Optimized 13-month Physical Exercise on (Early)-Postmenopausal Risk Factors in Women With Osteopenia and Osteoporosis (Actlife)

Menopause usually have a serious impact on a woman's life, associated with negative consequences for health and quality of life. Early preventive assessments are very difficult to implement due to the complex hormone-deficiency-induced effects on a large variety of organs and systems with estrogen receptors. In fact, only a few types of interventions have the potential to comprehensively improve the various risk factors and complaints of the menopausal transition. In detail, however, not every form of exercise training or every training protocol is effective for exerting positive effects on selected risk factors. In particular, the training concept for addressing musculoskeletal or cardio-metabolic risk factors differ fundamentally. In several studies, we confirmed the effect of different complex training programs on risk factors of different postmenopausal female cohorts with special consideration of osteoporotic aspects. The training programs applied in this context were characterized by the consistent implementation of recognized training principles and an in general exercise intensity-oriented approach. Recent studies confirmed the effectiveness of this proceeding for women with relevant postmenopausal risk factors including low bone strength. However, the crucial issue of the most effective, feasible and easily customizable training protocol for addressing postmenopausal risk factors remains to be answered, taking into account that the majority of exercise programs were realized in an ambulatory group setting. The aim of the study will be to evaluate the effects of an optimized physical training on risk factors and complaints of (early) postmenopausal women with special consideration of the osseous fracture risk. Note (05.06.2020): Of importance, the intervention has to be cancelled due to COVID-19 lockdown in March 2020 after 13 months of intervention.

NCT03959995 Osteopenia, Osteoporosis Other: High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT) Other: Wellness
MeSH:Osteoporosis Bone Diseases, Metabolic
HPO:Osteopenia

Primary Outcomes

Description: Bone Mineral Density (BMD) at the lumbar spine region of interest as determined by Dual Energy x-Ray Absorptiometry (DXA)

Measure: BMD Lumbar Spine

Time: from baseline to 13 month follow-up

Secondary Outcomes

Description: Bone Mineral Density at the total hip region of interest as determined by DXA

Measure: BMD total Hip

Time: from baseline to 13 month follow-up

Description: Muscle density at the para-vertebral region as determined by Magnetic Resonance Imaging (MRI)

Measure: Para-vertebral muscle density

Time: from baseline to 13 month follow-up

Description: Muscle density at the mid-thigh region as determined by MRI

Measure: Mid-thigh muscle density

Time: from baseline to 13 month follow-up

Description: Metabolic Syndrome Z-Score according to the Internationale Diabetes Federation (IDF)

Measure: Metabolic Syndrome

Time: from baseline to 13 month follow-up

Description: Visceral body fat as determined by Magnetic Resonance Imaging (MRI)

Measure: Visceral body fat

Time: from baseline to 13 month follow-up

Description: Total body fat as determined by whole body DXA

Measure: Total body fat

Time: from baseline to 13 month follow-up

Description: Total Lean Body Mass as determined by whole body DXA

Measure: Total Lean Body Mass

Time: from baseline to 13 month follow-up

Description: Menopausal complaints as determined by the Menopause Rating Scale (German version. Questionnaire with 11 items; scale from 0 (no complaints/problems) to 4 (very severe complaints/problem)

Measure: Menopausal complaints

Time: from baseline to 13 month follow-up

Description: Maximum isokinetic leg extensor strength as determined by an isokinetic leg press

Measure: Maximum leg strength

Time: from baseline to 13 month follow-up

Description: Total fat rate as determined by Bio Impedance technique (BIA)

Measure: Total fat rate

Time: from baseline to 13 month follow-up

Description: Fat free mass as determined by BIA

Measure: Fat free mass

Time: from baseline to 13 month follow-up


HPO Nodes


HP:0000938: Osteopenia
Genes 265
RSPRY1 SMARCAL1 SLC34A1 PDGFRB LIMK1 KCNJ1 MPLKIP MTAP B4GALT7 FGFR1 ESR1 FBN2 FSHR KISS1 ELN KRAS DPM2 PWAR1 GPR35 GTF2H5 SPRY4 PROP1 STAT3 TACR3 SLC9A3R1 FUT8 FGF17 MMP14 PLS3 ALDH18A1 PROP1 SCARB2 NR5A1 PLOD2 UROS FKBP14 AEBP1 PROK2 SMARCD2 SLC39A8 NPAP1 TCF4 ADAMTS2 DCHS1 RSPRY1 MAN2B1 COL1A1 GTF2E2 RNF113A PSAP SLC35A2 MMP2 CYP19A1 BMP15 FARSB BSCL2 MBTPS2 IGF1 ADCY10 COG1 STAT3 GPAA1 P3H1 ANTXR2 MAN2B1 GCM2 MLXIPL GNRHR LMNA GCM2 WDR11 EED NRAS SMPD1 SKI UNC80 ANOS1 FGFR1 SLC39A8 PSMB8 SLC39A13 COG1 GZF1 GNPAT MST1 NDN LIFR POLE SOX3 CDH23 GEMIN4 PHGDH BAZ1B TAF1 SEC24D CREB3L1 FOS IL17RD MMP1 GNPTAB CRTAP LRP5 ATP7A DCAF17 HERC2 MEN1 AGPAT2 GBA IER3IP1 COL1A1 ADAMTSL2 HSD17B4 PLOD3 MAGEL2 LMNA PMM2 HS6ST1 GNAS GTF2IRD1 P4HB ADAMTS2 PPARG CAVIN1 NUP107 XYLT2 SNORD115-1 CTC1 GPAA1 SH3PXD2B GFI1 MKRN3-AS1 PIGY NOTCH2 CHST3 RFC2 HPGD ELANE SLC17A5 SRP54 HBB GTF2I TONSL STAT1 SLC39A13 STN1 TRPV6 TAC3 PIGT PROKR2 SNRPN FLRT3 LMNA MMP2 BRAF CLIP2 RNU4ATAC IRX5 GORAB SLC34A1 SEC23A KISS1R FGF17 TMEM67 PRKACA GLIS3 SPIDR HESX1 ERCC3 DNAJC21 POLR3H HRAS UROS COX4I2 DCHS1 MAFB ATP6V0A2 ESR1 TRPS1 RNF125 GLI2 CRIPT CCND1 MKRN3 SRP54 SBDS ERCC2 DUSP6 PRKAR1A FOXA2 ANTXR2 DUSP6 LRP5 FKBP10 ANO5 MEN1 PYCR1 TCIRG1 AVP TARS1 B3GAT3 SNORD116-1 ELN NAGA CHD7 DDOST ZMPSTE24 TRPS1 MGAT2 FKBP14 FAT4 PLEKHM1 SERPINH1 TBL2 CTCF LHX4 PRLR CAV1 POLR3A NOTCH2 BNC1 SLC12A1 HECW2 RECQL4 PWRN1 SGMS2 PTH1R PIGT AIP PYGL CDC73 PDE11A USP9X PSMC3IP SLC7A7 OTX2 CAVIN1 FBN1 GNRH1 IFITM5 CDH23 IARS2 EIF2AK3 PSAT1 FAT4 IPW SKI FGF8 NPR2 NSMF TAPT1 ZMPSTE24 FGFR2 MRPS22 RPL11 ATP6V0A2 PMM2 ANO5 COL7A1 KISS1R STAT1 GATA1 B4GALT7 POU1F1 TMEM38B EFL1
Protein Mutations 2
H295R M184V
SNP 0